<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Epidemiology and etiology of osteomalacia</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Epidemiology and etiology of osteomalacia</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Epidemiology and etiology of osteomalacia</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Adi Cohen, MD, MHS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Matthew T Drake, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Deborah E Sellmeyer, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Katya Rubinow, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 18, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Osteomalacia is a disorder of decreased or defective mineralization of newly formed osteoid at sites of bone turnover, whereas rickets is a disorder of defective mineralization of cartilage in the epiphyseal growth plates of children. Osteomalacia and rickets can occur together in children (open growth plates), but only osteomalacia occurs in adults (fused growth plates). Several different disorders cause osteomalacia via mechanisms that result in hypocalcemia, hypophosphatemia, or direct inhibition of the mineralization process.</p><p>This topic will review the epidemiology, pathogenesis, and different causes of osteomalacia. The clinical manifestations, diagnosis, and treatment of osteomalacia and the etiology and treatment of rickets are discussed separately. (See  <a class="medical medical_review" href="/d/html/2040.html" rel="external">"Clinical manifestations, diagnosis, and treatment of osteomalacia in adults"</a> and  <a class="medical medical_review" href="/d/html/5804.html" rel="external">"Etiology and treatment of calcipenic rickets in children"</a>.)</p><p class="headingAnchor" id="H3169360"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>There is a growing prevalence of vitamin D deficiency in many countries [<a href="#rid1">1-4</a>]. Severe and prolonged vitamin D deficiency (25-hydroxyvitamin D &lt;10 ng/mL [25 nmol/L]) can result in hypocalcemia, secondary hyperparathyroidism, secondary hypophosphatemia, and osteomalacia [<a href="#rid5">5</a>]. Nutritional vitamin D deficiency is therefore an increasingly common cause of osteomalacia in adults. Populations at risk include homebound older adults who have little sun exposure and insufficient dietary calcium and vitamin D, patients with malabsorption (eg, related to gastrointestinal bypass surgery, inflammatory bowel disease, or celiac disease), and those with limited sun exposure due to clothing that covers most of the body or restrictions related to skin conditions [<a href="#rid6">6-10</a>]. Hereditary forms of vitamin D deficiency and resistance, which are identified in childhood, are also associated with osteomalacia in adults, but these disorders are less common.</p><p>Osteomalacia can also occur in patients with primary hypophosphatemia due to one of the hereditary hypophosphatemic rickets syndromes (eg, X-linked hypophosphatemic rickets, autosomal dominant hypophosphatemic rickets); these rare syndromes usually present in childhood but persist in adulthood. Hypophosphatemic osteomalacia presenting in adulthood may be due to tumor-induced osteomalacia, an acquired paraneoplastic syndrome of renal phosphate wasting. Drug-induced Fanconi syndrome can also result in renal phosphate wasting and osteomalacia. (See  <a class="medical medical_review" href="/d/html/5802.html" rel="external">"Hereditary hypophosphatemic rickets and tumor-induced osteomalacia"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>Bone remodeling occurs continually on both trabecular and Haversian (cortical) bone surfaces. At any given time, approximately 7 percent of the bone surface is in the process of forming new bone. The osteoclast begins the cycle by excavating a cavity on the bone surface followed by refilling of the cavity by activated osteoblasts. New bone formation takes place in two steps:</p><p class="bulletIndent1"><span class="glyph">●</span>Osteoblasts lay down organic matrix, or osteoid  (<a class="graphic graphic_picture graphicRef71593" href="/d/graphic/71593.html" rel="external">picture 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The matrix then undergoes a process of maturation, which requires the synthesis of a number of enzymes over a period of approximately 10 to 15 days [<a href="#rid11">11</a>]. At this point, bone mineral is deposited as amorphous calcium phosphate that undergoes conversion to hydroxyapatite. The calcium is taken up by mitochondria from the extracellular space and transported to matrix vesicles. The phosphate is made available by alkaline phosphatase present in the matrix vesicles.</p><p></p><p>The rates of bone formation and calcification can be measured by histomorphometric techniques using double <a class="drug drug_general" data-topicid="9986" href="/d/drug information/9986.html" rel="external">tetracycline</a> labeling [<a href="#rid12">12</a>]. Tetracyclines are deposited as a band at the mineralization front and these bands can be visualized under a fluorescence microscope. After two courses of the antibiotic, separated by a period of days, the growth rate of the skeleton can be estimated in iliac crest biopsies by measurement of the distance between the bands of deposited tetracycline.</p><p>Two changes occur in osteomalacia  (<a class="graphic graphic_picture graphicRef61773" href="/d/graphic/61773.html" rel="external">picture 2</a>) [<a href="#rid13">13</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The distance between <a class="drug drug_general" data-topicid="9986" href="/d/drug information/9986.html" rel="external">tetracycline</a> bands is reduced.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The unmineralized matrix appears as a widened osteoid seam (more than 15 microns) and the osteoid volume is more than 10 percent [<a href="#rid14">14</a>].</p><p></p><p>Both features are necessary for the diagnosis of osteomalacia because other disorders may show one of these findings [<a href="#rid13">13</a>]. (See  <a class="medical medical_review" href="/d/html/2040.html" rel="external">"Clinical manifestations, diagnosis, and treatment of osteomalacia in adults"</a>.)</p><p>Defective mineralization in osteomalacia is due to a lack of one or more of these necessary factors  (<a class="graphic graphic_table graphicRef70293" href="/d/graphic/70293.html" rel="external">table 1</a>) [<a href="#rid13">13</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Newly formed osteoid that is normal qualitatively and quantitatively. Fibrogenesis imperfecta ossium, osteogenesis imperfecta, and axial osteomalacia are examples of defective bone matrix formation and failure of mineralization despite normal plasma levels of calcium and phosphate.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Normal concentrations of calcium and phosphate in extracellular fluid to allow uptake of calcium and phosphate. Hypophosphatemia, due to vitamin D deficiency and secondary hyperparathyroidism or primary renal tubular defects with phosphate wasting, is a common cause of osteomalacia. (See  <a class="medical medical_review" href="/d/html/830.html" rel="external">"Hypophosphatemia: Causes of hypophosphatemia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Normal pH at the site of calcification. Chronic metabolic acidosis, as occurs in renal tubular acidosis, can affect mineralization.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Adequate bioactivity of alkaline phosphatase. Hypophosphatasia is a rare disease characterized by low alkaline phosphatase levels, which results in accumulation of pyrophosphate, an inhibitor of mineralization.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Absence of significant exposure to inhibitors of calcification, such as older bisphosphonates (eg, <a class="drug drug_general" data-topicid="8426" href="/d/drug information/8426.html" rel="external">etidronate</a>), aluminum, and, occasionally, high doses of fluorides. (See  <a class="medical medical_review" href="/d/html/2024.html" rel="external">"Pharmacology of bisphosphonates", section on 'Mineralization'</a>.)</p><p></p><p class="headingAnchor" id="H10"><span class="h1">ETIOLOGY</span><span class="headingEndMark"> — </span>Several different disorders cause osteomalacia via mechanisms that result in hypocalcemia, hypophosphatemia, or direct inhibition of the mineralization process  (<a class="graphic graphic_table graphicRef70293" href="/d/graphic/70293.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H11"><span class="h2">Vitamin D deficiency and resistance</span><span class="headingEndMark"> — </span>Vitamin D deficiency or resistance may result in osteomalacia by one of four mechanisms [<a href="#rid15">15</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Impaired availability of vitamin D, secondary to inadequate dietary vitamin D, fat malabsorptive disorders, and/or lack of photoisomerization</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Impaired 25-hydroxylation of vitamin D in the liver to 25-hydroxyvitamin D (eg, due to severe liver disease)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Impaired 1 alpha-hydroxylation of 25-hydroxyvitamin D in the kidney to 1,25-dihydroxyvitamin D</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>End-organ insensitivity to vitamin D metabolites (hereditary vitamin D-resistant rickets)</p><p></p><p>The most common cause of osteomalacia worldwide is dietary vitamin D deficiency combined with lack of sun exposure and, in the United States, gastrointestinal disease or postsurgical states with altered intestinal absorption. Causes of vitamin D deficiency are reviewed separately. (See  <a class="medical medical_review" href="/d/html/2048.html" rel="external">"Causes of vitamin D deficiency and resistance"</a> and  <a class="medical medical_review" href="/d/html/5804.html" rel="external">"Etiology and treatment of calcipenic rickets in children"</a>.)</p><p class="headingAnchor" id="H2373955404"><span class="h2">Inadequate calcium intake</span><span class="headingEndMark"> — </span>Inadequate intake of calcium may contribute to the development of osteomalacia [<a href="#rid1">1,16</a>]. Among African children with rickets in whom exposure to sunlight was adequate, the intake of calcium (with or without vitamin D supplementation) was superior to vitamin D alone in improving the biochemical and radiographic manifestations of rickets [<a href="#rid17">17</a>]. Although the exact cause of rickets in these children was unclear, sufficient ingestion of calcium as well as vitamin D in childhood appears essential for adequate skeletal formation. (See  <a class="medical medical_review" href="/d/html/5804.html" rel="external">"Etiology and treatment of calcipenic rickets in children", section on 'Calcium deficiency'</a>.)</p><p class="headingAnchor" id="H13"><span class="h2">Hypophosphatemia</span><span class="headingEndMark"> — </span>In disorders of vitamin D metabolism, hypophosphatemia can be an important contributor to osteomalacia. In these settings, secondary hyperparathyroidism can lead to urinary phosphate wasting. Disorders that cause calcitriol deficiency also result in impaired intestinal absorption of phosphate as well as calcium. (See  <a class="medical medical_review" href="/d/html/2048.html" rel="external">"Causes of vitamin D deficiency and resistance", section on 'Vitamin D-dependent rickets type IA (VDDR-1A)'</a>.)</p><p>Primary renal phosphate wasting syndromes can be inherited or acquired, either as an idiopathic disorder or in association with mesenchymal tumors (tumor-induced osteomalacia) [<a href="#rid18">18</a>] (see  <a class="medical medical_review" href="/d/html/5802.html" rel="external">"Hereditary hypophosphatemic rickets and tumor-induced osteomalacia"</a>). The use of parental polymaltose-containing iron infusions has also been reported to cause hypophosphatemia-associated osteomalacia [<a href="#rid19">19</a>]. These disorders result from excessive circulating levels of the phosphaturic hormone, fibroblast growth factor 23 (FGF23), or other phosphaturic proteins (sometimes referred to collectively as "phosphatonins").</p><p>Renal phosphate wasting can also occur as part of an overall defect in proximal tubular transport in Fanconi syndrome. In adults, Fanconi syndrome is commonly caused by multiple myeloma, which is often latent [<a href="#rid20">20</a>]. It has also been reported in the context of exposure to several medications, including antivirals (tenofovir, <a class="drug drug_general" data-topicid="8690" href="/d/drug information/8690.html" rel="external">adefovir</a>), aminoglycoside antibiotics, sodium <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a>, and fumaric acid esters [<a href="#rid21">21-26</a>], and after exposure to heavy metals, such as cadmium. (See  <a class="medical medical_review" href="/d/html/2328.html" rel="external">"Etiology and diagnosis of distal (type 1) and proximal (type 2) renal tubular acidosis", section on 'Proximal (type 2) RTA'</a> and  <a class="medical medical_review" href="/d/html/7202.html" rel="external">"Epidemiology and toxicity of cadmium", section on 'Kidney disease'</a>.)</p><p class="headingAnchor" id="H14"><span class="h2">Chronic kidney disease</span><span class="headingEndMark"> — </span>Bone disease in chronic kidney disease is due to a number of factors, including reduced formation of 1,25-dihydroxyvitamin D (calcitriol), metabolic acidosis, and administration of aluminum. Historically, aluminum-containing antacids were the predominant cause of osteomalacia in this setting but are now much less commonly used because other, safer phosphate binders are now commonly available. (See  <a class="medical medical_review" href="/d/html/1942.html" rel="external">"Management of hyperphosphatemia in adults with chronic kidney disease"</a> and  <a class="medical medical_review" href="/d/html/1839.html" rel="external">"Aluminum toxicity in chronic kidney disease"</a>.)</p><p class="headingAnchor" id="H15"><span class="h2">Renal tubular acidosis</span><span class="headingEndMark"> — </span>Osteomalacia or rickets is most often seen with proximal (type 2) renal tubular acidosis/Fanconi syndrome [<a href="#rid27">27</a>]. In this setting, proximal phosphate wasting, metabolic acidosis, and secondary hyperparathyroidism may all contribute to the decrease in bone mineralization. Metabolic acidosis can both promote calcium loss and directly impair mineralization. (See <a class="local">'Pathogenesis'</a> above.)</p><p>Although the association is controversial, osteomalacia has also been reported in patients with distal (type 1) renal tubular acidosis [<a href="#rid28">28-30</a>]. In one study, for example, two of seven patients with Sjögren's disease and distal renal tubular acidosis also had findings consistent with osteomalacia [<a href="#rid28">28</a>]. Osteopenia and decreased bone formation have been described in this setting, with correction of acidosis increasing the bone formation rate [<a href="#rid28">28</a>]. (See  <a class="medical medical_review" href="/d/html/2328.html" rel="external">"Etiology and diagnosis of distal (type 1) and proximal (type 2) renal tubular acidosis"</a>.)</p><p class="headingAnchor" id="H16"><span class="h2">Mineralization inhibitors</span><span class="headingEndMark"> — </span>Osteomalacia is occasionally due to mineralization inhibitors. Included in this group are:</p><p class="bulletIndent1"><span class="glyph">●</span>Bisphosphonates, which have a structure similar to native pyrophosphate, an important inhibitor of mineralization [<a href="#rid31">31</a>]. Continuous use of <a class="drug drug_general" data-topicid="8426" href="/d/drug information/8426.html" rel="external">etidronate</a>, a non-nitrogenous bisphosphonate, has been associated with mineralization defects. However, there are differences among the bisphosphonates in their potential to inhibit mineralization and cause osteomalacia. The circulating concentrations of the nitrogen-containing bisphosphonates currently in use (eg, <a class="drug drug_general" data-topicid="9427" href="/d/drug information/9427.html" rel="external">alendronate</a>, <a class="drug drug_general" data-topicid="10242" href="/d/drug information/10242.html" rel="external">risedronate</a>, <a class="drug drug_general" data-topicid="8887" href="/d/drug information/8887.html" rel="external">ibandronate</a>, and <a class="drug drug_general" data-topicid="9902" href="/d/drug information/9902.html" rel="external">zoledronic acid</a>) do not cause osteomalacia. (See  <a class="medical medical_review" href="/d/html/2024.html" rel="external">"Pharmacology of bisphosphonates", section on 'Mineralization'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Aluminum, which has been implicated in osteomalacia in patients with chronic kidney disease as well as in those receiving total <a class="drug drug_general" data-topicid="10307" href="/d/drug information/10307.html" rel="external">parenteral nutrition</a> and amino acids in the form of casein hydrolysate [<a href="#rid32">32,33</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8462" href="/d/drug information/8462.html" rel="external">Fluoride</a>, which can cause osteomalacia when ingested in excessive quantities, as may occur in endemic fluorosis [<a href="#rid34">34</a>] and with ingestion of fluoride toothpastes and certain teas [<a href="#rid35">35</a>].</p><p></p><p class="headingAnchor" id="H17"><span class="h2">Hypophosphatasia</span><span class="headingEndMark"> — </span>Hypophosphatasia is a rare, genetic disease, characterized by mutations in the tissue non-specific alkaline phosphatase (TNSALP) gene, leading to a diminished activity of the TNSALP enzyme in target tissues and accumulation of TNSALP substrates, including inorganic pyrophosphate, an inhibitor of mineralization [<a href="#rid36">36,37</a>]. Clinical features include low levels of alkaline phosphatase in serum and bone and the development of osteomalacia and periodontal disease. Owing to the large number of described mutations in the TNSALP gene and variable clinical expression, there is a very wide range of disease severity ranging from lethal perinatal forms to milder fracture phenotypes that present in adulthood or isolated dental manifestations (premature loss of deciduous teeth and/or extensive dental caries).</p><p class="bulletIndent1"><span class="glyph">●</span>In infancy and childhood, features of hypophosphatasia [<a href="#rid37">37</a>] may include hypotonia, respiratory compromise, rachitic deformities, delayed walking and gait abnormalities, craniosynostosis, recurrent fractures, bone pain and short stature, premature loss of deciduous teeth, and seizures.</p><p></p><p class="bulletIndent1">The availability of enzyme replacement therapy with <a class="drug drug_general" data-topicid="104963" href="/d/drug information/104963.html" rel="external">asfotase alfa</a> (recombinant tissue-nonspecific isoenzyme of alkaline phosphatase [TNSALP]) for the treatment of childhood-onset hypophosphatasia has altered the natural history of this condition [<a href="#rid38">38</a>]. (See  <a class="medical medical_review" href="/d/html/2040.html" rel="external">"Clinical manifestations, diagnosis, and treatment of osteomalacia in adults", section on 'Other causes'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In adulthood, hypophosphatasia is most commonly characterized by the presence of poorly healing, recurrent fractures (commonly affecting the extremities), and bone pain (thighs and hips), as well as an increased incidence of pyrophosphate arthropathy and chondrocalcinosis [<a href="#rid37">37,39-41</a>].</p><p></p><p class="bulletIndent1">In adolescents and adults with hypophosphatasia, <a class="drug drug_general" data-topicid="104963" href="/d/drug information/104963.html" rel="external">asfotase alfa</a> may improve motor function [<a href="#rid42">42</a>].</p><p></p><p class="headingAnchor" id="H18"><span class="h2">Defective bone matrix</span><span class="headingEndMark"> — </span>Axial osteomalacia is a rare, generalized skeletal disorder of defective bone mineralization that presents with chronic axial skeletal pain, most often in the cervical spine [<a href="#rid43">43</a>]. Men are affected more often than women, and it may be familial. Radiographic abnormalities (coarsened trabecular pattern) are seen in the spine and pelvis. Histopathologic studies of bone reveal osteoidosis and failure of <a class="drug drug_general" data-topicid="9986" href="/d/drug information/9986.html" rel="external">tetracycline</a> deposition. The pathogenesis is uncertain, but genetic etiologies and an association with sacroiliitis have been suggested [<a href="#rid44">44,45</a>].</p><p>Fibrogenesis imperfecta ossium is a very rare, progressive, idiopathic disorder of defective bone matrix formation and impaired mineralization [<a href="#rid46">46,47</a>]. Symptoms begin in adult life with pain, fractures, and weakness. Serum alkaline phosphatase may be elevated, consistent with a mineralization defect. It affects the entire skeleton and is characterized pathologically by the absence of normal birefringent collagen fibrils. Some cases have been associated with a monoclonal or polyclonal gammopathy. The cause is unknown.</p><p class="headingAnchor" id="H3169891"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis</strong> – Osteomalacia is a disorder of defective mineralization of newly formed osteoid at sites of bone turnover. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1">Mineralization abnormalities occur as a consequence of inadequate calcium, phosphate, vitamin D, and/or alkaline phosphatase levels, or in the presence of abnormal bone matrix or direct inhibition of the mineralization process. (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Etiology</strong> – Several different disorders cause osteomalacia. Severe vitamin D deficiency (25-hydroxyvitamin D &lt;10 ng/dL [25 nmol/L]), secondary to inadequate dietary intake, lack of sun exposure, or conditions leading to gastrointestinal malabsorption, is the most common cause of osteomalacia in adults. (See <a class="local">'Etiology'</a> above and  <a class="medical medical_review" href="/d/html/2048.html" rel="external">"Causes of vitamin D deficiency and resistance"</a>.)</p><p></p><p class="bulletIndent1">Other causes include hereditary or acquired disorders of phosphate wasting, type 2 renal tubular acidosis, and excessive exposure to inhibitors of bone mineralization (eg, aluminum toxicity, endemic fluorosis)  (<a class="graphic graphic_table graphicRef70293" href="/d/graphic/70293.html" rel="external">table 1</a>). (See <a class="local">'Etiology'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Uday S, Högler W. Nutritional Rickets and Osteomalacia in the Twenty-first Century: Revised Concepts, Public Health, and Prevention Strategies. Curr Osteoporos Rep 2017; 15:293.</a></li><li><a class="nounderline abstract_t">Cashman KD, Dowling KG, Škrabáková Z, et al. Vitamin D deficiency in Europe: pandemic? Am J Clin Nutr 2016; 103:1033.</a></li><li><a class="nounderline abstract_t">Prentice A. Nutritional rickets around the world. J Steroid Biochem Mol Biol 2013; 136:201.</a></li><li><a class="nounderline abstract_t">Munns CF, Shaw N, Kiely M, et al. Global Consensus Recommendations on Prevention and Management of Nutritional Rickets. J Clin Endocrinol Metab 2016; 101:394.</a></li><li><a class="nounderline abstract_t">Ashwell M, Stone EM, Stolte H, et al. UK Food Standards Agency Workshop Report: an investigation of the relative contributions of diet and sunlight to vitamin D status. Br J Nutr 2010; 104:603.</a></li><li><a class="nounderline abstract_t">Kennel KA, Drake MT, Hurley DL. Vitamin D deficiency in adults: when to test and how to treat. Mayo Clin Proc 2010; 85:752.</a></li><li><a class="nounderline abstract_t">Al-Shoha A, Qiu S, Palnitkar S, Rao DS. Osteomalacia with bone marrow fibrosis due to severe vitamin D deficiency after a gastrointestinal bypass operation for severe obesity. Endocr Pract 2009; 15:528.</a></li><li><a class="nounderline abstract_t">Karefylakis C, Näslund I, Edholm D, et al. Vitamin D status 10 years after primary gastric bypass: gravely high prevalence of hypovitaminosis D and raised PTH levels. Obes Surg 2014; 24:343.</a></li><li><a class="nounderline abstract_t">Dedeoglu M, Garip Y, Bodur H. Osteomalacia in Crohn's disease. Arch Osteoporos 2014; 9:177.</a></li><li><a class="nounderline abstract_t">Shikino K, Ikusaka M, Yamashita T. Vitamin D-deficient osteomalacia due to excessive self-restrictions for atopic dermatitis. BMJ Case Rep 2014; 2014.</a></li><li><a class="nounderline abstract_t">Ansari S, de Wildt BWM, Vis MAM, et al. Matrix Vesicles: Role in Bone Mineralization and Potential Use as Therapeutics. Pharmaceuticals (Basel) 2021; 14.</a></li><li><a class="nounderline abstract_t">Dempster DW, Compston JE, Drezner MK, et al. Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2013; 28:2.</a></li><li><a class="nounderline abstract_t">Russell JA. Osteomalacic myopathy. Muscle Nerve 1994; 17:578.</a></li><li><a class="nounderline abstract_t">Parfitt AM, Pødenphant J, Villanueva AR, Frame B. Metabolic bone disease with and without osteomalacia after intestinal bypass surgery: a bone histomorphometric study. Bone 1985; 6:211.</a></li><li><a class="nounderline abstract_t">Reginster JY. The high prevalence of inadequate serum vitamin D levels and implications for bone health. Curr Med Res Opin 2005; 21:579.</a></li><li><a class="nounderline abstract_t">Pettifor JM. Nutritional rickets: deficiency of vitamin D, calcium, or both? Am J Clin Nutr 2004; 80:1725S.</a></li><li><a class="nounderline abstract_t">Thacher TD, Fischer PR, Pettifor JM, et al. A comparison of calcium, vitamin D, or both for nutritional rickets in Nigerian children. N Engl J Med 1999; 341:563.</a></li><li><a class="nounderline abstract_t">Sommer S, Berndt T, Craig T, Kumar R. The phosphatonins and the regulation of phosphate transport and vitamin D metabolism. J Steroid Biochem Mol Biol 2007; 103:497.</a></li><li><a class="nounderline abstract_t">Bishay RH, Ganda K, Seibel MJ. Long-term iron polymaltose infusions associated with hypophosphataemic osteomalacia: a report of two cases and review of the literature. Ther Adv Endocrinol Metab 2017; 8:14.</a></li><li><a class="nounderline abstract_t">Clarke BL, Wynne AG, Wilson DM, Fitzpatrick LA. Osteomalacia associated with adult Fanconi's syndrome: clinical and diagnostic features. Clin Endocrinol (Oxf) 1995; 43:479.</a></li><li><a class="nounderline abstract_t">Hall AM, Bass P, Unwin RJ. Drug-induced renal Fanconi syndrome. QJM 2014; 107:261.</a></li><li><a class="nounderline abstract_t">Balak DM, Bouwes Bavinck JN, de Vries AP, et al. Drug-induced Fanconi syndrome associated with fumaric acid esters treatment for psoriasis: a case series. Clin Kidney J 2016; 9:82.</a></li><li><a class="nounderline abstract_t">Girgis CM, Wong T, Ngu MC, et al. Hypophosphataemic osteomalacia in patients on adefovir dipivoxil. J Clin Gastroenterol 2011; 45:468.</a></li><li><a class="nounderline abstract_t">Kim du H, Sung DH, Min YK. Hypophosphatemic osteomalacia induced by low-dose adefovir therapy: focus on manifestations in the skeletal system and literature review. J Bone Miner Metab 2013; 31:240.</a></li><li><a class="nounderline abstract_t">Shimizu Y, Hiraoka A, Yamago H, et al. Hypophosphatemia in patients with hepatitis B virus infection undergoing long-term adefovir dipivoxil therapy. Hepatol Res 2014; 44:1081.</a></li><li><a class="nounderline abstract_t">Koenig KF, Kalbermatter S, Menter T, et al. Recurrent bone fractures due to tenofovir-induced renal phosphate wasting. Scand J Infect Dis 2014; 46:221.</a></li><li><a class="nounderline abstract_t">Brenner RJ, Spring DB, Sebastian A, et al. Incidence of radiographically evident bone disease, nephrocalcinosis, and nephrolithiasis in various types of renal tubular acidosis. N Engl J Med 1982; 307:217.</a></li><li><a class="nounderline abstract_t">Fulop M, Mackay M. Renal tubular acidosis, Sjögren syndrome, and bone disease. Arch Intern Med 2004; 164:905.</a></li><li><a class="nounderline abstract_t">Disthabanchong S, Domrongkitchaiporn S, Sirikulchayanonta V, et al. Alteration of noncollagenous bone matrix proteins in distal renal tubular acidosis. Bone 2004; 35:604.</a></li><li><a class="nounderline abstract_t">Cherif E, Ben Hassine L, Kaoueche Z, Khalfallah N. Osteomalacia as inaugural manifestation of Sjögren syndrome. BMJ Case Rep 2013; 2013.</a></li><li><a class="nounderline abstract_t">Adamson BB, Gallacher SJ, Byars J, et al. Mineralisation defects with pamidronate therapy for Paget's disease. Lancet 1993; 342:1459.</a></li><li><a class="nounderline abstract_t">Ott SM, Maloney NA, Klein GL, et al. Aluminum is associated with low bone formation in patients receiving chronic parenteral nutrition. Ann Intern Med 1983; 98:910.</a></li><li><a class="nounderline abstract_t">Vargas JH, Klein GL, Ament ME, et al. Metabolic bone disease of total parenteral nutrition: course after changing from casein to amino acids in parenteral solutions with reduced aluminum content. Am J Clin Nutr 1988; 48:1070.</a></li><li><a class="nounderline abstract_t">Wang Y, Yin Y, Gilula LA, Wilson AJ. Endemic fluorosis of the skeleton: radiographic features in 127 patients. AJR Am J Roentgenol 1994; 162:93.</a></li><li><a class="nounderline abstract_t">Kurland ES, Schulman RC, Zerwekh JE, et al. Recovery from skeletal fluorosis (an enigmatic, American case). J Bone Miner Res 2007; 22:163.</a></li><li><a class="nounderline abstract_t">Linglart A, Biosse-Duplan M. Hypophosphatasia. Curr Osteoporos Rep 2016; 14:95.</a></li><li><a class="nounderline abstract_t">Whyte MP. Hypophosphatasia - aetiology, nosology, pathogenesis, diagnosis and treatment. Nat Rev Endocrinol 2016; 12:233.</a></li><li><a class="nounderline abstract_t">Whyte MP, Simmons JH, Moseley S, et al. Asfotase alfa for infants and young children with hypophosphatasia: 7 year outcomes of a single-arm, open-label, phase 2 extension trial. Lancet Diabetes Endocrinol 2019; 7:93.</a></li><li><a class="nounderline abstract_t">Maman E, Borderie D, Roux C, Briot K. Absence of recognition of low alkaline phosphatase level in a tertiary care hospital. Osteoporos Int 2016; 27:1251.</a></li><li><a class="nounderline abstract_t">Högler W, Langman C, Gomes da Silva H, et al. Diagnostic delay is common among patients with hypophosphatasia: initial findings from a longitudinal, prospective, global registry. BMC Musculoskelet Disord 2019; 20:80.</a></li><li><a class="nounderline abstract_t">Bianchi ML, Bishop NJ, Guañabens N, et al. Hypophosphatasia in adolescents and adults: overview of diagnosis and treatment. Osteoporos Int 2020; 31:1445.</a></li><li><a class="nounderline abstract_t">Kishnani PS, Rockman-Greenberg C, Rauch F, et al. Five-year efficacy and safety of asfotase alfa therapy for adults and adolescents with hypophosphatasia. Bone 2019; 121:149.</a></li><li><a class="nounderline abstract_t">Whyte MP, Fallon MD, Murphy WA, Teitelbaum SL. Axial osteomalacia. Clinical, laboratory and genetic investigation of an affected mother and son. Am J Med 1981; 71:1041.</a></li><li class="breakAll">Whyte MP. Sclerosing Bone Disorders. In: Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, Seventh Edition, Rosen CJ (Ed), American Society of Bone and Mineral Research, Washington, DC 2008. p.412.</li><li><a class="nounderline abstract_t">Rolland T, Gensburger D, Chavassieux P, Chapurlat R. Axial osteomalacia: a new case report. Joint Bone Spine 2010; 77:482.</a></li><li><a class="nounderline abstract_t">Lang R, Vignery AM, Jensen PS. Fibrogenesis imperfecta ossium with early onset: observations after 20 years of illness. Bone 1986; 7:237.</a></li><li><a class="nounderline abstract_t">Bhadada SK, Dhaliwal R, Dhiman V, Rao SD. Fibrogenesis Imperfecta Ossium. Calcif Tissue Int 2019; 104:561.</a></li></ol></div><div id="topicVersionRevision">Topic 2045 Version 19.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28612338" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Nutritional Rickets and Osteomalacia in the Twenty-first Century: Revised Concepts, Public Health, and Prevention Strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26864360" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Vitamin D deficiency in Europe: pandemic?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23220549" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Nutritional rickets around the world.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26745253" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Global Consensus Recommendations on Prevention and Management of Nutritional Rickets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20522274" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : UK Food Standards Agency Workshop Report: an investigation of the relative contributions of diet and sunlight to vitamin D status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20675513" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Vitamin D deficiency in adults: when to test and how to treat.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19491072" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Osteomalacia with bone marrow fibrosis due to severe vitamin D deficiency after a gastrointestinal bypass operation for severe obesity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24163201" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Vitamin D status 10 years after primary gastric bypass: gravely high prevalence of hypovitaminosis D and raised PTH levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24847674" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Osteomalacia in Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25100811" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Vitamin D-deficient osteomalacia due to excessive self-restrictions for atopic dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33805145" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Matrix Vesicles: Role in Bone Mineralization and Potential Use as Therapeutics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23197339" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8196699" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Osteomalacic myopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3840379" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Metabolic bone disease with and without osteomalacia after intestinal bypass surgery: a bone histomorphometric study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15899107" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The high prevalence of inadequate serum vitamin D levels and implications for bone health.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15585795" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Nutritional rickets: deficiency of vitamin D, calcium, or both?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10451461" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : A comparison of calcium, vitamin D, or both for nutritional rickets in Nigerian children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17224271" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The phosphatonins and the regulation of phosphate transport and vitamin D metabolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28203361" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Long-term iron polymaltose infusions associated with hypophosphataemic osteomalacia: a report of two cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7586624" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Osteomalacia associated with adult Fanconi's syndrome: clinical and diagnostic features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24368854" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Drug-induced renal Fanconi syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26798466" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Drug-induced Fanconi syndrome associated with fumaric acid esters treatment for psoriasis: a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20661153" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Hypophosphataemic osteomalacia in patients on adefovir dipivoxil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22976054" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Hypophosphatemic osteomalacia induced by low-dose adefovir therapy: focus on manifestations in the skeletal system and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24033734" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Hypophosphatemia in patients with hepatitis B virus infection undergoing long-term adefovir dipivoxil therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24147545" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Recurrent bone fractures due to tenofovir-induced renal phosphate wasting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7088070" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Incidence of radiographically evident bone disease, nephrocalcinosis, and nephrolithiasis in various types of renal tubular acidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15111378" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Renal tubular acidosis, Sjögren syndrome, and bone disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15336595" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Alteration of noncollagenous bone matrix proteins in distal renal tubular acidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24108773" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Osteomalacia as inaugural manifestation of Sjögren syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7902484" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Mineralisation defects with pamidronate therapy for Paget's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6407375" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Aluminum is associated with low bone formation in patients receiving chronic parenteral nutrition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3138907" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Metabolic bone disease of total parenteral nutrition: course after changing from casein to amino acids in parenteral solutions with reduced aluminum content.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8273699" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Endemic fluorosis of the skeleton: radiographic features in 127 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17014382" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Recovery from skeletal fluorosis (an enigmatic, American case).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27084188" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Hypophosphatasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26893260" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Hypophosphatasia - aetiology, nosology, pathogenesis, diagnosis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30558909" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Asfotase alfa for infants and young children with hypophosphatasia: 7 year outcomes of a single-arm, open-label, phase 2 extension trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26446772" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Absence of recognition of low alkaline phosphatase level in a tertiary care hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30764793" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Diagnostic delay is common among patients with hypophosphatasia: initial findings from a longitudinal, prospective, global registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32162014" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Hypophosphatasia in adolescents and adults: overview of diagnosis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30576866" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Five-year efficacy and safety of asfotase alfa therapy for adults and adolescents with hypophosphatasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7315848" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Axial osteomalacia. Clinical, laboratory and genetic investigation of an affected mother and son.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7315848" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Axial osteomalacia. Clinical, laboratory and genetic investigation of an affected mother and son.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20591721" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Axial osteomalacia: a new case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3490268" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Fibrogenesis imperfecta ossium with early onset: observations after 20 years of illness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31069441" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Fibrogenesis Imperfecta Ossium.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
